September 2, 2022
The Japanese government will distribute AstraZeneca’s recently approved long-acting antibody combination Evusheld (tixagevimab/cilgavimab) only for the prevention of COVID-19, the health ministry said in a notification issued on September 1. In Japan, Evusheld was approved on August 30 both for...read more